Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Neurooncol. 2013 Oct 27;116(1):89–97. doi: 10.1007/s11060-013-1283-3

Fig. 5. PTEN status determines survival with 2ME2 treatment in an orthotopic brain tumor model.

Fig. 5

The effects of 2ME2 on survival in an orthotopic brain tumor mouse model implanted with U373MG PTEN-Null (A) and U373MG-PTEN (B) cells. Survival data represents 6–8 animals per experimental group. Beginning on post-implantation day 3, 2ME2 or a vehicle control were administered IP once daily at 200mg/kg. Among mice bearing tumors derived from U373MG PTEN-Null cells, there was no significant benefit in survival with 2ME2 versus vehicle control treatment (P=0.869). In mice bearing tumors derived from U373MGPTEN-reconstituted cells, there was a significant prolongation in survival among the 2ME2 treatment group versus vehicle controls (P= 0.028).